跳至主要内容
临床试验/NCT05107245
NCT05107245已完成不适用

Observational Study on the Diagnostic Evaluation of the Intestinal Microbiota of French People Infected With the SARS-CoV-2.

Luxia Scientific4 个研究点 分布在 1 个国家目标入组 143 人开始时间: 2020年4月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
143
试验地点
4
主要终点
Alpha-diversity

研究概览

简要总结

In the context of the COVID-19 pandemic, the role of the gut microbiome is yet unknown. The aim of this trial is to evaluate the clinical contribution of the gut microbiome composition and diversity on the disease severity and to estimate the viral load in stool samples.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 95 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • COVID-19 positive patients: hospitalised patients diagnosed with COVID-19 in one of the investigating sites, and able to provide a stool sample.
  • Control subjects: Medical and paramedical personnel working at one of the investigating sites, having been in direct contact with the patients.
  • Aged between 18 and 95 years.
  • Subjects able to read the French-language study information leaflet.
  • Patients with social cover.

排除标准

  • COVID-19 negative patients.
  • Patients in critical care, heart failure or respiratory failure.
  • Unable to provide naturally a stool sample.
  • Patients without social cover.
  • Pregnant women

结局指标

主要结局

Alpha-diversity

时间窗: at the time of inclusion in the study

Alpha-diversity of the gut microbiota measured by 16S sequencing

次要结局

  • Microbiome composition(at the time of inclusion in the study)
  • SARS-CoV-2 load(at the time of inclusion in the study)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验